Stephen Doberstein

Dr. Doberstein is an expert in protein engineering with over 20 years of experience in the design and development of antibody, cytokine, and fusion protein drugs. After receiving a Ph.D. in Cell Biology at Johns Hopkins University School of Medicine and postdoctoral training at UC Berkeley, Dr. Doberstein held positions at successful biotech companies including Director Cell Biology at Exelixis and was VP, Research at Xencor, FivePrime Therapeutics, and Xoma. He most recently served as Chief R&D Officer at Nektar Therapeutics. Dr. Doberstein sat on the Board of Directors of Dicerna prior to the company’s acquisition by Novo Nordisk, and is a member of the Biotechnology Advisory Board of the University of Delaware.